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NTRODUCTION
The conduct of a General Anesthesia is generally 
compared to a flight travel – here the intubation is 
akin to take off and extubation to landing. Hence the 
intubation and extubation are the most stressful 
events to the patient. Though the art of attenuating 
the stress response to intubation is practiced 
widely, the practice of caring about the stress 
response to extubation is not practiced widely. But 
the stress during extubation can be detrimental and 
life threatening in a wide group of patient 
population. 
Though a pilot gives equal attention to landing and take off, we 
anesthesiologist  are mostly  concentrating on intubation rather  than on 
extubation in relation to stress response. The present study attempts to 
redress this imbalance. 
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 HISTORY
The  introduction  of  anaesthesia  dates  back  to  16  october  1846, 
when W.T.G Mortan of Boston anaesthetised Gilbert Abbott. 
Endotracheal  techniques  were  popularised  by  Ivan  W.Magil and 
E.Stanley Rowbotham in early 1920’s. Controlled respiration was then 
established following the use of curare by  Harold Griffith and  G.Enid 
johnson of  Montreal  in  1942.  Macintosh described  his  curved 
laryngoscope in Oxford in 1943.
From  then  on,  anaesthesia  has  become  much  safer  with  the 
subsequent introduction of various techniques and newer drugs to deal 
with  untoward  complications.  Subsequently  the  rude  way  of 
anaesthetising a patient has evolved into a systematic and well organised 
job with subsequent researches studying and concentrating on the most 
tiny details. This paved the way for the evolution of anaesthesia into an 
individual speciality.  Of late,  anaesthesiologists have been trying very 
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hard  to  maintain  the  near  normal  physiological  vitals  throughout 
anaesthesia using the relevant drugs and techniques. 
The  cardiovascular  responses  to  laryngoscopy  and  endotracheal 
intubation have been recognised since 1951. Consequently drugs were 
used  to  control  the  stress  response  during  intubation  and  to  a  minor 
degree  during  extubation.  Subsequently,  the  mortality  and  morbidity 
during anaesthesia decreased. 
AIMS OF THE STUDY
 To  quantify  the  amount  of  cardiovascular  stress  response 
during extubation 
 To  prove  the  effectiveness  of  intravenous  diltiazem, 
verapamil and lidocaine in attenuating stress response during 
extubation. 
To know whether these drugs can have an effect on the quality 
of extubation. 
 
9
                                GENERAL ANAESTHESIA
In  1957,  P.WOODBRIDGE defined  general  anasthesia  as 
comprising of four components:
1. sleep or unconsciousness 
2. blockade of undesirable reflexes  
3. motor blockade 
4. sensory blockade. 
These ideas have been discussed and modified by M.Pinsker into 3 
components.
1. paralysis 
2. unconsciousness 
3. attenuation of stress response. 
Lundy’s balanced anaesthesia is  another  formulation of  the idea 
that several drugs can be used in continuation to produce the state of 
unconsciousness and analgesia that we define as general anaesthesia.
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General anaesthesia can also be defined as a carefully controlled 
reversible  modification  or  depression  of  various  modalities  of  central 
nervous  system,  autonomic  nervous  system  and  peripheral  nervous 
system  by  using  small,  incremental,  titrated  doses  of  various 
pharmacological agents to achieve a specific physiological goal, the goal 
being the protection of the patient from the detrimental effects of various 
reflexes. 
General anaesthesia comprises of three aspects, well known as the 
"Triad of Anaesthesia" (i.e) Hypnosis, Analgesia, Reflex Suppression. 
ANALGESIA REFLEX SUPPRESSION
1
INDUCTION       HYPNOSIS      RECOVERY
 
This  triad  can  be achieved by using  small,  titrated,  incremental 
doses  of  various  pharmacological  agents,  thereby  gaining  maximum 
benefit of each drug, at the same time avoiding their side effects. 
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(Sleep)
General Anaesthesia is usually provided by endotracheal intubation 
and controlled ventilation.  At  the end of  the anaesthesia  endotracheal 
extubation is done. Tracheal extubation can be associated with various 
problems. 
General Anaesthesia with endotracheal intubation is considered as 
the safest form of anaesthesia, since, here the airway is under the control 
of the anaesthesiologist. But this is not absolutely safe since problems 
during the last but not the least step (ie.) extubation can be fatal. 
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PROBLEMS DURING EXTUBATION
1. Difficult extubation: 
Difficulty  in  removing  a  tracheal  tube  at  the  end  of  a  General 
Anaesthesia is a rare, but dangerous and occasionally fatal complication 
of difficult intubation.
Causes:
 Failure to deflate the tracheal tube cuff. 
 An excessively large cuff catching on the vocal cords. 
 Adhesion of the tube to the tracheal wall because of 
the absence of lubricant. 
 Tube being transfixed by a suture. 
2. CARDIO VASCULAR RESPONSE TO EXTUBATION 
3. Trauma to vocal cords and upper and lower airway 
4. Tracheal collapse, due to tracheomalacia 
5. Airway obstruction. 
Laryngospasm
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Supraglottic edema
Laryngeal edema Retroarytenoidal edema 
Subglottic edema 
Vocal cord paralysis
6. Pulmonary edema 
7. Laryngeal incompetence
Laryngeal incompetence leading to aspiration of gastric contents or 
foreign bodies at tracheal extubation. 
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CARDIOVASCULAR RESPONSES TO EXTUBATION 
AND ITS IMPLICATIONS
Tracheal extubation is performed usually with the 
patient in a light stage of anaesthesia and produces 
significant increases in heart rate and arterial 
pressure. 
The exact mechanism of these cardiovascular response in man is 
unknown,  but  it  is  believed  to  be  associated  with  the  release  of 
catecholanines causing increases in heart rate,  myocardial contractility 
and systemic vascular resistance. 
CLINICAL SIGNIFICANCE:
The  majority  of  patients  are  able  to  tolerate  the  hemodynamic 
responses to tracheal extubation without any significant consequences. 
However,  patients  with  coexisting  disease  may  be  unable  to  tolerate 
these responses, while others will have an exaggerated response which 
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may be poorly tolerated. 
CARDIOVASCULAR SYSTEM:
In  patients  with  coronary  artery  disease,  the  haemodynamic 
responses  to  extubation  may  upset  the  delicate  balance  between 
myocardial  oxygen  supply  and  demand,  resulting  in  myocardial 
ischemia.  An  ischemic  myocardial  metabolic  response  to  tracheal 
extubation has also been demonstrated in some patients after coronary 
artery surgery.
 
Although suppression of the hemodynamic response to extubation 
is  unlikely  to  influence  the  outcome in  the  majority  of  patients  with 
stable  coronary  arteries,  there  remains  a  small  number  of  patients  in 
whom  a  single  hyperdynamic  episode  may  produce  a  clinical 
catastrophe.  Thus  it  is  reasonable  to  attempt  to  minimize  the  stress 
response to tracheal extubation. 
In  both  treated  and  untreated  hypertensive  patients,  tracheal 
extubation  is  associated  with  significant  increases  in  heart  rate  and 
arterial  pressure.  These  increase  mimic  in  size  those  associated  with 
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laryngoscopy  and  tracheal  intubation.  Such  hypertensive  crisis  may 
result  in  cardiac  decompensation,  pulmonary  edema  or  cerebral 
haemorrhage. 
CENTRAL NERVOUS SYSTEM:
In  patients  who  have  undergone  neurosurgical  operations,  the 
hypertensive response to tracheal extubation may be detrimental. In such 
patients, autoregulation of cerebral blood flow may be disturbed and a 
sudden  increase  in  arterial  pressure  may  lead  to  increases  in  both 
cerebral blood flow and intracranial pressure. These increases may result 
in either herniation of brain contents or decrease in cerebral perfusion 
pressure, leading to cerebral ischemia. It seems reasonable, therefore, to 
attempt to prevent or suppress the haemodynamic response to extubation 
in such patients. 
Thus the sympatho-adrenal response to extubation may be harmful 
in  those  suffering  from systemic  hypertension,  myocardial  ischaemia, 
intracranial  hypertension,  cerebrovascular  disease  and  valvular  heart 
disease. 
Further, the integrity of cerebral and aortic aneurysms is largely a 
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function of  transmural  pressure.  A sudden increase  in  blood pressure 
during  extubation  can  lead  to  rupture  of  these  vessels  and  sudden 
deterioration. 
CARDIOVASCULAR REFLEXES: 
Both the sympathetic and parasympathetic nervous systems play a 
role in the cardiovascular responses to extubation.
The  hypertension  and  tachycardia  response  to  extubation  are 
mediated through sympathetic efferents via cardio accelerator nerves and 
sympathetic  chain ganglia.  This  reflex is  polysynaptic in  nature.  This 
reflex is mediated by the glossophayngeal nerve, when the stimuli occurs 
superior to the anterior surface of the epiglottis and by the vagus nerve, 
when stimuli occur from the level of posterior surface of the epiglottis 
down into the lower airway. These stimuli passes through the brainstem 
and  spinal  cord  and  results  in  diffuse  autonomic  responses,  which 
includes  widespread  release  of  noradrenaline  from  adrenergic  nerve 
terminals and secretion of adrenaline from adrenal medulla. 
Some  of  the  hypertensive  responses  to  endotracheal  extubation 
also result from activation of renin-angiotensin system, with the release 
of renin from the renal juxtaglomerular apparatus. 
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REVIEW OF LITERATURE
Edde RR  in 1979 demonstrated the cardiovascular  responses to 
extubation. He suggested that tracheal extubation was performed usually 
with the patient in a light stage of anaesthesia and produced significant 
increases in heart rate and arterial pressure.
Wohlner  and  Colleagues  in  1979,  studied  the  hemodynamic 
responses to tracheal extubation in patients after coronary artery surgery. 
They  demonstrated  significant  increases  in  heart  rate,  mean  arterial 
pressure, cardiac index and systemic vascular resistance index. They also 
demonstrated similar significant increases in the mean pulmonary artery 
pressure, pulmonary artery occlusion pressure and pulmonary vascular 
resistance index. 
Dyson et al in 1990 demonstrated in 10 ASA I and II patients who 
were  not  receiving  cardiovascular  or  antihypertensive  medication,  in 
whom extubation was performed, an increase of 20% or more in both 
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heart rate and systolic arterial pressure, in 70% of the patients. 
Lowrie A et al in 1992 showed a significant increase in the plasma 
concentration  of  adrenaline,  but  not  of  noradrenaline,  after  tracheal 
extubation  in  a  small  group  of  patients  who  had  undergone  major 
elective surgery. 
Prys – Roberts C et al in 1971 have shown that the cardiovascular 
responses to intubation is associated with the release of catecholamines 
causing  increases  in  heart  rate,  myocardial  contractility  and  systemic 
vascular resistance. 
Hodgkinson  R  et  al  in  1980  studied  parturiants  with  severe 
preeclampsia and suggested that the cardiovascular response to tracheal 
extubation is as dramatic as the response to tracheal intubation.  They 
demonstrated mean maximal increases of 45 mm Hg in mean systemic 
arterial pressure, 20mm Hg in mean pulmonary arterial pressure and 20 
mm Hg in pulmonary artery occlusion pressure, in relation to tracheal 
extubation.
Bidwai  AV  et  al  in  1978  demonstrated  that  the  tracheal 
administration  of  lignocaine,  60  mg  ,3-5  min  before  extubation  and 
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lignocaine, 40 mg at extubation ,prevented increases in heart rate and 
arterial pressure during and after tracheal extubation. They subsequently 
in the year 1979 demonstrated that iv administration of lignocaine 1mg 
per kg, 2 mins before tracheal extubation also prevented the stress of 
extubation. 
Dyson  et  al  in  1990  demonstration  that  esmolol  attenuates  the 
cardiovascular stress response to extubation. 
Fujjii  Y  et  al  in  1999  showed  that  combined  diltiazem  and 
lidocaine is more effective prophylaxis than diltiazem or lidocaine alone 
for attenuating the cardiovascular responses to tracheal extubation. 
Shajur MA et  al  in  1999 demonstrated  that  remifentanil  bolus 
dose of 1mg/kg prevented the  in HR and MAP at the time of extubation 
without any effect on recovery. 
Kihara S et al in 1998 showed that the administration of diltiazem 
produced greater attenuation of the haemodynamic response to tracheal 
extubation than nicardipine. 
Nishina K et al in 1995 concluded that a bolus dose of intravenous 
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fentanyl 2mg / kg given at the time of peritoneal closure was of value in 
attenuating  the  cardiovascular  changes  associated  with  tracheal 
extubation and that this did not prolong the recovery. 
Kovac Ac  in 2001 have shown that  nicardipine in the doses of 
0.03mg/kg  attenuated  the  blood  pressure  but  not  heart  rate  response 
during emergence and extubation. 
Wang Y Q et al in 2003 found that esmolol in 1.5mg/kg does not 
only controlled cardiovascular response to tracheal extubation, but also 
had no side effects. 
Yorukoglu D et  al in 1999 Showed that  metoprolol  effectively 
blocked the increases on heart rate after extubation and the increase in 
blood pressure was less when compared to the control groups. 
Nishina K et al in 1996 showed that prostaglandin E1 infusion of 
0.1mg/kg/min was effective in attenuating hypertensive responses during 
extubation but ineffective for tachycardia.
Zalunareto MP et al showed that a single preoperative iv dose of 
clonidine (3mg/kg) blunts the hemodynamic responses due to extubation 
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in noncardiac surgery of intermediate duration. 
Yoshitake MD and his colleagues showed that combined diltiazem 
and  lidocaine  administration  during  tracheal  extubation  for  stress 
attenuation was more effective than either drug alone. 
Mikaeva Katsuya et  al  in  1997 showed that  a  combination  of 
verapamil  0.1  mg/kg  and  lidocaine  1mg/kg  injected  iv  two  minutes 
before extubation was superior to either drug alone in attenuating stress 
response to extubation. 
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                           MATERIALS AND METHODS
After obtaining approval from the ethical committee 
of the Department of Anaesthosiology, Government 
Rajaji Hospital and Madurai Medical College, 
Madurai, the study was conducted in 120 patients 
posted for elective surgeries under general 
anaesthesia. 
Informed  consent  was  obtained  from  the  patients  before 
conducting the study. 
Type of Study:
Prospective study
Double blind study.
Inclusion criteria:
Elective  surgical  patients  between  20-65 yrs  of  age,  who  came 
under ASA physical status I were included in the study. 
24
Exclusion criteria:
ASA physical status II, III & IV
Age < 20 & > 65 yrs.
Patients suffering from coexisting systemic illness and those taking 
cardiovascular or antihypertensive medications.
Patients who required postoperative ventilation.
Preoperative preparation:
Routine  preoperative  assessment  as  for  any  elective  surgical 
patient was carried out. 
The patients were randomly divided into four groups.  (n=30 for 
each group).
Group S Saline control group
Group V 0.1mg/kg verapamil group
Group D 0.2 mg/kg diltiazem group
Group L 1.5mg/kg lidocaine group
Premedication: 
Once  the  patient  was  found  to  be  fit,  premedication  was 
administrated.
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All patients were premedicated with intramuscular atropine 0.6mg 
and intramuscular pentazocine 0.06mg/kg ,45 mins before the induction 
of anaesthesia. 
The following emergency drugs and equipments were kept ready
 Boyle’s machine with oxygen cylinder 
 Laryngoscopes with varied blades 
 Oropharyngeal airway 
 Endotracheal tubes 
 Drugs  -  atropine,  adrenaline,  ephedrine,  dexamethasone, 
Deriphyline.
Baseline pulse rate and Blood pressure were recorded. 
Intravenous line was secured with 18 G Cannula. 
Patients were preoxygenated for 3 minutes with 100% oxygen via 
Mapleson’s A circuit with mask. 
Anaesthesia was induced with Inj thiopentone sodium 5mg/kg iv as 
2.5%  solution  and  tracheal  intubation  was  facilitated  with  Inj 
succinylcholine 2mg/kg iv. 
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Anaesthesia was maintained with 66% nitrous oxide in oxygen and 
titrated,  intermittent  bolus  doses  of  Inj  pentazocine  iv  and  inj 
pancuromium iv. 
Monitoring during anaesthesia was done with pulse oximetry and 
non invasive BP. 
Pulse rate, Blood pressure and SPO2, were monitored throughout 
the surgery. 
After surgery N2O was discontinued and residual muscle relaxation 
was reversed with inj neostigmine, 0.04 mg/kg and inj atropine 0.02 mg/
kg. iv. Three minutes later saline (Group S) or verapamil (Group V) or 
diltiazem ( Group D) or lidocaine (Group L) were given iv according to 
the group of the patient. These medications had been prepared before and 
in  equivalent  volumes  and  their  identities  were  unknown  to  the 
anaesthetist. The trachea was extubated 2 minutes after administration of 
the study drugs. Immediately before tracheal extubation it was confirmed 
that the patients were able to breath spontaneously and open their eyes 
on  command.  The  recovery  from muscle  relaxation  was  assessed  by 
hand grip. Oropharyngeal secretions were aspirated immediately prior to 
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extubation. After tracheal extubation, 100% oxygen was given via face 
mask for 5 mins.
 
 Monitored Parameters:
Systolic arterial pressure (SAP)
Diastolic arterial Pressure (DAP) &
Heart rate (HR)
were measured at the time of injection of neostigmine and atropine 
mixure. 
Hemeodynamic  data  was  then  recorded  every  minute  until  5 
minutes after extubation. 
The  Systolic  Arterial  Pressure,  Diastolic  Arterial  Pressure  and 
Heart rate measured at the time of injection of neostigmine and atropine 
mixture was taken as the baseline value. 
Haemodynamic  data  obtained from 3  min  after  the  injection  of 
neostigmine  atropine  mixture  (i.e.  at  the  time  of  injection  of  study 
medications)  until  5  min after  extubation were  analysed  to  determine 
cardiovascular changes associated with tracheal extubation. Values for 
28
SAP,  DAP  and  HR  found  immediately  before  the  induction  of 
anaesthesia, at the time of injection of neostigmine –atropine mixture, at 
the  time  of  injection  of  the  study  drugs  (  2min  before  tracheal 
extubation), 1 min after these drugs (1 min before tracheal extubation), at 
tracheal extubation and 1 min and 5 min after tracheal extubation were 
compared among the four groups.
 
QUALITY OF EXTUBATION:
The quality of tracheal extubation was evaluated using a five-point 
rating scale. 
1 – no coughing or straining
2 – very smooth, with minimal coughing
3 – moderate coughing
4 – marked coughing or straining
5 – poor extubation, very uncomfortable.
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CALCIUM CHANNEL BLOCKERS
 (calcium entry blockers or calcium antagonists)
 These are a diverse group of structurally unrelated compounds that 
selectively  interfere  with  inward  calcium  ion  movement  across 
myocardial and vascular smooth muscle cells. 
 Calcium ions play a key role in the electrical excitation of cardiac 
cells and vascular smooth muscle cells. 
Classification:
On basis of chemical structure into
(a) phenyl alkyl amines
(eg) verapamil
(b) 1,4 – dihydropyridines
(eg) nifedipine
(c) benzothiazepines 
(eg) diltiazem.
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Calcium Channels:
Three types of calcium channels have been 
described in smooth muscles and other excitable 
cells of the body. 
They are:
a. Voltage sensitive channel 
b. Receptor operated channel. 
c. Leak channel. 
Voltage sensitive Ca  2+   Channels :  
These are heterogenous – three major types have been identified 
L - type,
T – type &
N – Type.
All voltage sensitive Ca2+ channels are membrane spanning funnel 
shaped  glycoproteins  that  function  as  ion  selective  valves.  They  are 
composed of a major subunit, which encloses the ion channel and other 
modulatory subunits. The channels exist in multiple isoforms which may 
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be site specific. Only the voltage sensitive L – type channels are blocked 
by  the  CCBs.  The  three  groups  of  CCBs  bind  to  their  own  specific 
binding sites  on the  α 1  subunit-  all  restricting Ca2+ entry,  though the 
characteristics of the channel blockade differ.
Pharmacological actions of CCB:
The common property of all 3 subclasses of CCBs is to inhibit 
Ca2+  mediated  slow  channel  component  of  the  action  potential  in 
smooth / cardiac muscle cell.
Two important actions are
i. Smooth muscle (specially vascular) relaxation. 
ii. Negative chronotropic, inotropic and dromotropic actions 
on the heart. 
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PHARMACOLOGY OF VERAPAMIL:
History:
Verapamil  was  developed  in  Germany  in  1962  as  a  coronary 
dilator. 
Fleckenstein in 1967 showed that it interfered with Ca2+ movement 
into the cell. 
Verapamil  is  a  synthetic  hydrophilic  papaverine  congener 
belonging to the phenylalkylamine group of calcium channel blockers. 
Physiochemical properties:
It is supplied as a racemic mixture.
The  dextroisomer  of  verapamil  is  devoid  of  activity  at  slow 
calcium channels and instead acts on fast sodium channels, accounting 
for the local anaesthetic effects.
The  levoisomer  is  specific  for  slow  channel  blockade  and  the 
predominance of this action accounts for the classification of verapamil 
as a calcium channel blocker.
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Mechanism of action:
Verapamil binds to the intracellular portion of the α 1 subunit of the 
L-type channel subunit, when the channel is in an open state and actually 
physically  occlude  the  channel.  It  further  delays  the  recovery  of  the 
channel.
Pharmacokinetics: 
Absorption:
Oral verapamil is almost completely absorbed.
Oral absorption > 90%
But  oral  bioavailability  is  only  10-20%  because  of  extensive 
hepatic first pass metabolism with high hepatic extraction of 75-90% of 
orally  administered drug.  As a  result  oral  dose is  about 10 times the 
intravenous dose. 
Protein binding:
 Verapamil  is  highly  protein  bound  upto  90%.  The  presence  of 
other drugs like lidocaine,  diazepam and propranolol  can increase the 
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pharmacologically active, unbound portion of the drug. 
Metabolism and clearance:
It is metabolilsed in liver and excreted in urine and bile.
Dimethylated  metabolites  of  verapamil  predominate,  with 
norverapamil  possessing  sufficient  activity  to  contribute  to  the 
antidysrhythmic properties of the parent drug.
70% of injected dose is recovered in urine as metabolites and 15% 
is excreted via bile.
Onset of action:
Oral  < 30 minutes
Intravenous              1 - 3 minutes
Therapeutic plasma concentration:
100 – 300 ng/ml
Volume of distribution (Vd):
5 liters / kg
Elimination half time: 
4-6 hours
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Dosage:
Oral - 80 – 160 mg tds
Intravenous   - 75 –150 micro grams / kg
Availability:
40, 80 mg tablets.
120, 240 mg slow release tablets.
5mg / ml injection
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EFFECTS OF VERAPAMIL ON VARIOUS 
SYSTEMS OF THE BODY
Cardiovascular system:
Of the many CCBs verapamil has the most 
prominent cardiac electrophysiological action. 
Negative chronotropic effect:
This effect is due to slowing of the SA node. It results in reduced 
myocardial oxygen consumption.  The direct negative chronotropic 
effects of  verapamil  are  able  to  overcome  any  reflex  sympathetic 
response to the lowering of blood pressure. This effect can depress the 
frequency of hyperactive tissue causing arrhythmias. 
The  basic  action  of  verapamil  is  to  depress  Ca2+ mediated 
depolarization. 
Suppresses automaticity or reentry dependent on slow response.
Phase 4 depolarization in SA node and purkinjee fibres is reduced 
resulting in bradycardia and extinction of latent pacemakers. 
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The  most  consistent  action  of  verapamil  is  prolongation  of  AV 
nodal ERP. As a result AV conduction is markedly slowed and reentry 
involving AV node is terminated. 
Intraventricular conduction, however, is not affected.
Negative inotropic effect:
This effect reduces myocardial oxygen consumption. Verapamil's 
direct  negative  inotropic  effects  are  able  to  overcome  any  reflex 
sympathetic response to the lowering of blood pressure.
 Negative dromotropic effect:
By slowing conduction through the AV node, verapamil increases 
the time needed for each beat. This results in reduced myocardial oxygen 
consumption.
  Effect on smooth muscles:
Verapamil  dilates  the  arterioles  and  has  some  α adrenergic 
blocking activity  –  decreases total  peripheral  resistance but  the blood 
pressure is only modestly lowered. The heart rate generally decreases, 
AV conduction  is  slowed,  but  cardiac  output  is  maintained by reflex 
sympathetic stimulation and decrease in aortic impedance. 
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Verapamil is a potent vasodilator of coronary vessels. This effect 
increases coronary blood flow, and reduces coronary vasospasm. 
Indications:
1. Paroxysmal supraventricular tachycardia : 
Verapamil is a class IV antiarrhythmic drug. 
It  terminates  attacks  of  paroxysmal  supraventricular 
tachycardia. It is also useful for preventing recurrences 
2. Atrial fibrillation or flutter:
To control ventricular rate in atrial fibrillation or flutter.
3. Hypertension: 
Lowers BP by decreasing peripheral vascular resistance without 
compromising cardiac output. 
The vasodilatory effects of verapamil are useful in treating mild 
to moderate hypertension, particularly low-renin hypertension. 
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intravenous verapamil may be effective in treating hypertensive 
emergencies.
4. Angina Pectoris: 
Reduces frequency and severity of classical as well as variant 
angina.  Benefit  in  classical  angina  appears  primarily  due  to 
reduction  in  cardiac  work-  mainly  as  a  result  of  reduced 
afterload due to peripheral vasodilatation. 
It also increases coronary flow. 
Exercise tolerance is increased. 
Capacity of verapamil to prevent arterial spasm is responsible 
for the beneficial effect in variant angina. 
Reduction of cardiac O2 demand would also work in the same 
direction.
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5. Hypertrophic cardiomyopathy: 
The negative inotropic action of verapamil can be salutary in 
the diastolic dysfunction in this condition.
6. Premature labour: 
Due to its action on smooth muscle       relaxant effect.
7. Maternal and fetal tachy dysrhythmias: 
Administered intravenously in parturients,  verapamil prolongs 
atrioventricular conduction of the fetus despite limited placental 
transfer of the drug.
8. Nocturnal leg cramps. 
 
Adverse effects:
Nausea,Constipation, Dizziness & Bradycardia are more common
Flushing, Headache &Ankle Edema are less common
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Contraindications: 
 
1.CHF:
Patients  with  reduced  ventricular  function  may  not  be  able  to 
counteract the inotropic and chronotropic effects of verapamil, the result 
being an even higher compromise of function.
2. SA node or AV conduction disturbances: 
Use  of  verapamil  is  contraindicated in  patients  with  SA or  AV 
nodal  abnormalities,  because  of  its  negative  chronotropic and 
dromotropic effects 
3. Low blood pressure: 
Patients with systolic blood pressures below 90 mm Hg should not 
be treated with verapamil. 
4. Digitalis toxicity: 
Verapamil  is  contraindicated  for  atrial  tachycardia  caused  by 
digitalis toxicity,because of pharmacokinetic interactions that may lead 
to increased blood digoxin levels. 
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4. Wolff-Parkinson-White syndrome induced atrial fibrillation:
Verapamil  may  paradoxically  increase  ventricular  rate  in  some 
patients because of accessory conduction pathways. 
Drug interactions:
1.  β   - Blockers: 
Additive sinus depression.
I.V.  verapamil  should  never  be  used  concurrently  with  a  beta-
blocker;  can  result  in  AV  block  or  severe  depression  of  ventricular 
function and asystole may occur.
2.  Digoxin  : 
Verapamil  increases  plasma  concentration  of  digoxin  –  causing 
increased toxicity, presumably by decreasing its plasma clearance.
3.Qunidine and disopyramide:
Additive cardiac depression and reduced clearance. 
4.Volatile anaesthetics:
One of the possible mechanism of cardiac depression by volatile 
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agents is interference with calcium movement across the cell membrane.
The myocardial  depression and peripheral  vasodilation produced 
by volatile agents could be exaggerated by similar actions of verapamil. 
5.Neuromuscular blocking agents:
Verapamil  potentiate  the  effects  of  depolarizing  and 
nondepolarising muscle relaxant. 
The local  anaesthetic effect  of verapamil  reflecting inhibition of 
sodium  ion  flux  via  fast  sodium  channels  –  may  contribute  to  the 
potentiation of these agents. 
Further  the  antagonism  of  neuromuscular  blockade  may  be 
impaired because of diminished presynaptic release of acetylcholine due 
to verapamil. 
6.Local anaesthetic:
Verapamil increases the risk of local anaesthetic toxicity.
7.Potassium containing solutions:
Verapamil slows the inward movement of potassium ions. 
So  there  is  a  risk  of  hyperkalemia  when  administered  with 
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potassium containing solutions (or) with stored blood. 
8.Dantrolene: 
Verapamil  alters  the  normal  homeostatic  mechanisms  for 
regulation  of  plasma  potassium  concentrations  and  may  result  in 
hyperkalemia from dantrolene induced potassium release. 
PHARMACOLOGY OF DILTIAZEM
Diltiazem is a Benzothiazepine calcium channel blocker. 
Mechanism of action: 
 Act at the L-Type calcium channel on the α1 subunit. But the 
mechanism of action is not well understood. 
 It may act on sodium – potassium pump, decreasing the amount 
of  intracellular  sodium  available  for  exchange  with 
extracellular calcium. 
 It may inhibit calcium calmodulin binding. 
Pharmacokinetics: 
Absorption: 
Oral absorption is excellent >90%
Bioavailability: 
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Only 40% due to  first-pass  hepatic  extraction  of  about  70-80% 
after oral administration.
Protein binding:
70-80% bound to proteins.
Metabolism and clearance:
Extensively metabolized in liver and excreted as active metabolites 
principally in bile (60%) and to a lesser extent in urine (35%)
Onset of action:
Oral --30 minutes
Intravenous --1-3 minutes
Therapeutic plasma concentration: 
100 -250 nanograms / ml
Volume of distribution :
3 liters / kilogram
Elimination half time:
5-6 hrs
Dosage: 
Oral 60-90 mg 8th hourly 
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Intravenous 75-150 mg / kg
Availability: 
60 mg and 30 mg oral tablets.
90 mg slow release tablets.
25 mg / 5 ml intravenous injections. 
Effects on cardiovascular system: 
Diltiazem has a modest direct negative inotropic action, but direct 
depression of SA mode and AV conduction are equivalent to verapamil. 
 
Effects on smooth muscle: 
Less potent vasodilator than verapamil. 
Usual clinical doses produce consistent fall in BP with little change 
or decrease in heart rate. 
Large  dose  or  iv  injection  decreases  total  peripheral  resistance 
markedly which may elicit reflex cardiac effects. 
It dilates the coronaries.
Indications:
Similar to that of verapamil.
1. Paroxysmal suprarentricular tachycardia: 
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Used as an alternative to verapamil.
2. Atrial fibrillation and flutter: 
To control the ventricular rate.
3. Angina pectoris. 
4. Hypertension. 
Contraindications: 
1. Patients with sick sinus syndrome 
2. 2nd or 3rd degree AV block 
3. Patients with severe hypotension or cardiogenic shock 
4. Hypersensitivity to the drug. 
5. Patients on intravenous β - blockers. 
6. Patients with atrial fibrillation or flutter associated with an 
accessory bypass tract such as in WPW syndrome or short 
PR interval. 
7. Patients  with  ventricular  tachycardia  –  ventricular 
fibrillation may be precipitated. 
48
Adverse effects:
Are mild and transient. 
Hypotension, injection-site reactions, vasodilatation, arrythmias – 
junctional  bradycardia,  chestpain,  CCF,  pruritis,  constipation,  nausea, 
dizziness,  vomiting,  headache,  paresthesia,  amblyopia,  exfoliative 
dermatitis.
Drug interactions:
1. Anaesthetic drugs:
The  depression  of  cardiac  contractility,  conductivity  and 
automaticity  as  well  as  the  vascular  dilatation  associated  with 
anaesthetics may be potentiated by diltiazem. 
2. Digitalis: 
Since  both  digitalis  and  diltiazem affect  AV  nodal  conduction, 
patients should be monitored for excessive slowing of the heart rate and 
AV block.
3. Beta blockers: 
Due to additive action, the possibility of bradycardia, AV block, 
depression of myocardial contractility should be considered. 
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PHARMACOLOGY OF LIDOCAINE
Lidocaine  is  a  synthetic  amide-linked  local  anaesthetic  of 
intermediate  potency  and  duration.  In  1943  Lofgren synthesized 
lidocaine in Sweden. First used by Gordh in 1948.
Lidocaine is the standard to which all other local anaesthetics are 
compared.  It  is  currently  the  most  widely  used  local  anaesthetic.  In 
addition,  it  is  a  popular  antiarrythmic.  It  can be given by almost  any 
route.
 
Mechanism of action: 
Lidocaine  prevent  transmission  of  nerve  impulses  by  inhibiting 
passage  of  sodium ions  through ion-selective  sodium channels  in  the 
nerve membranes.  This  slows the rate  of  depolarization such that  the 
threshold  potential  is  not  reached  and  thus  action  potential  is  not 
propagated.  But  resting  membrane  potential  is  not  altered.  Lidocaine 
binds to the inner portion receptor (i.e sodium channel) after entering the 
cell membrane. 
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Physiochemical properties:
Molecular weight 234. 
Weak base with a pka 7.6 – 7.8. 
Very stable, not decomposed by boiling, acids or alkalies. 
It is less lipid soluble than that of Bupivacaine. 
 
Pharmacokinetics:
Absorption:
It  is  absorbed  from the  site  of  application  or  injection  into  the 
blood stream. Rate of absorption depends on the blood flow to the area 
and use of epinephrine. 
Metabolism: 
Metabolised in liver by oxidative dealkylation to monoethylglycine 
xylidide  followed  by  hydrolysis  of  this  metabolite  to  xylidide. 
Metabolism is dependant on hepatic blood flow.
Monoethylglycine xylidide has 80% activity of the parent drug.
Xylidide has 10% activity of the parent drug. 
75% of xylidide is excreted in the urine as 4 – hydroxyl – 2,6, 
-dimethylaniline.
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Onset of action: 
Rapid onset of action.
• Topical anaesthesia 5-10 mins
• Conduction anaesthesia
 For small nerves 5-10 mins
 For large nerves 10-15 mins
• Intravenous administration 1-2 mins
Protein binding: 
It is 70% bound to α1 acid glycoproteins.
Volume of distribution: 
91 liters
Distribution: 
Lignocaine has a triphasic distribution. 
Rapid distribution phase (α ) :
In this phase, the drug is distributed to highly vascular regions. 
t ½ α is 1 min.
Slow disappearance phase ( β ) : 
The drug is distributed to slowly equilibrating tissues. 
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t ½ β is 9.6 min.
Slow transformation and excretion phase ( δ ) :
t ½ δ is 1.6 hrs. 
Clearance is 0.95 litres per minute.
Availability: 
a. 5% heavy 2 ml ampoules which contain 50mg of lignocaine / ml 
with 75 mg – 100 mg of dextrose. 
b. 2% lignocaine (xylocard)  without preservative – 50 ml  vial  for 
intravenous use. 
c. 2% lignocaine – plain – 30 ml vial – contains methyl and propyl 
paraben as preservative.
d. 4% lignocaine with 1 in 200000 Adrenaline ─ 30─ ml vial. 
e. 4% Lignocaine viscus 
f. 4% lignocaine aqueous solution 
g. 10% lignocaine spray 
h. 2% lignocaine jelly 
i. 2% lignocaine ointment 
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j. 5% lignocaine ointment
Pharmacodynamics: 
Local actions: 
Causes nerve blockade with loss of pain and temperature sensation, 
touch, motor power and vasomotor tone in the region supplied by the 
nerves blocked. 
Systemic actions: 
Result  of  systemic  absorption  from  the  site  of  admistration  or 
intravenous administration.
Cardiovascular system:
It has a stabilizing effect on the cell membranes of cardiac tissue. 
Lignocaine depresses myocardial automaticity by antagonizing the 
spontaneous  phase  IV  depolarization  and  reduces  the  duration  of 
effective refractory period. 
Myocardial contractility and conduction velocity are depressed at 
higher concentrations. 
These effects result from direct cardiac muscle membrane changes 
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(ie.) cardiac sodium channel blockade. 
It stabilizes the membrane of damaged and excitable cells, tending 
to suppress ectopic foci..
Respiratory system: 
Lignocaine  depresses  hypoxic  drive  (the  ventilatory  response  to 
low PaO2 .)
Apnea can result from phrenic and intercostal nerve paralysis or 
depression of the medullary respiratory center following direct exposure 
to the local anaesthetic agents. 
Relax bronchial smooth muscle. 
Intravenous  lignocaine  may  be  effective  in  blocking  the  reflex 
bronchoconstriction associated with intubation. 
Vascular smooth muscle: 
Produces vasodilatation. 
Central nervous system:
Produces a sequence of stimulation followed by depression.
Produces sedation on intravenous administration.
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Intravenous  administration  decreases  cerebral  blood  flow  and 
attenuates the rise in intracranial pressure that accompanies intubation. 
Infusion of lignocaine is capable of reducing the MAC of volatile 
anaesthetics by 40% 
Musculoskeletal  :  
Lignocaine is myotoxic leading to lytic degeneration, edema and 
necrosis.
Haematological   : 
It decreases coagulation and enhances fibrinolysis. 
Indications: 
1. For  infiltration  block,  peripheral  nerve  blocks,  epicdural,  spinal 
and topical anaesthesia & intravenous regional anaesthesia. 
2. Antiarrythmic: 
Lignocaine is a class I B antiangthrimic. 
 Ventricular tachydrythmias 
 Arythmias following acute MI during cardiac surgery 
 In digitalis toxicity – because it does not worsen AV- 
56
block. 
3. Prevention or treatment of increases in intracranial pressure during 
intubation. 
- antitussive effect may be the reason. 
4. Reflex  induced  bronchospasm  is  also  attenuated  by  iv 
administration of lignocaine. 
5. Suppresses  noxious  reflexes  such  as  coughing  &  sympathetic 
stimulations  associated  with  endotracheal  suctioning  and 
intubation.
6. Used as an antiepileptic agent intravenously.
7. Used intravenously as an analgesic for certain chronic pain states. 
8. Used as a supplement to general anaesthesia. 
Contraindications:
 Hypersensitivity.
 Should not be used with vasoconstrictor in digits of 
hand, feet and penis.
 Stokes Adams syndrome, severe degree of heart block
Dose: 
Maximum recommended dose
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(a) plain - 3 mg/kg
(b) with adrenaline - 7 mg/kg
(c) for reflex suppression - 1.5mg/kg iv.
Drug interactions: 
β Blockers: 
Coadministration  of  betablockers,  increases  serum  levels  of 
lignocaine and its toxicity by decreasing lignocaine’s metabolism.
Anticonvulsant agents: 
Increases lignocaine’s metabolism.
Non depolarizing muscle relaxant:
Blockade is potentiated by lignocaine. 
Opioids and α 2 adrenergic agonists:
Potentiate lignocaine’s pain relief. 
Antiarrythmic agents: 
Potentiate the cardiac effects of lignocaine.
Toxicity:
Mostly  due  to  systemic  absorption  of  locally  administered 
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lignocaine or due to accidental intravenous administration of large doses 
of lignocaine. 
The cental nervous system is mostly vulnerable.
Blood levels and symptoms
4mg/ml: lightheadedness,  tinnitus,  circumoral  and  tongue 
numbness [anticonvulsant and antiarrhythmic activity]
6mg/ml: visual disturbances. 
8mg/ml: muscular twitching 
10mg/ml: convulsions 
12mg/ml: unconsciousness 
15mg/ml: coma 
20mg/ml: respiratory arrest
26mg/ml: cardiovascular collapse 
Treatment of toxicity: 
Continuous monitoring of CVS and RS status.
 If convulsions occur barbiturates or benzodiazepines can be 
given. 
 Succinylcholine 1mg/kg to paralyse the patient
 Cardiac  toxicity  like  fibrillation  can  be  treated  by 
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defibrillation.
 Ventilatory support –100% oxygenation , intubation etc.,
 Maintain  B.P.  by  rapid  infusion  of  I.V.  fluids,  use  of 
vasopressors and put the patient in Trendelenberg’s position.
 Maintain fluid and electrolyte balance.
Adverse effects: 
1. Allergic and hypersensitivity reactions: 
Due to the preservative used - methyparaben. 
2. Neurotoxicity: 
Transient radicular irritation 
Cauda equina syndrome
Anterior spinal artery syndrome. 
3. CVS: 
Bradycardia, hypotension.
OBSERVATION AND RESULTS  
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Data among groups are analysed by using one-way 
analysis of variance and are assessed by using 
NeumanKeuls post-hoc test. Data within each group are 
analysed by using two-way analysis of variance followed 
by using Bonferroni’s correction of t-test. 
DEMOGRAPHIC DATA 
1. Comparison between groups with respect to Sex 
Sum of 
Squares 
Df Mean Square F Sig.
PRDIFF  Between Groups    
                Within Groups 
                Total 
293.461
49096.53
9
49390.00
0
1
118
119
293.461
416.072
.705 .403
SDIFF     Between Groups 
                Within Groups 
                Total   
103.187
54135.73
8
54238.92
5
1
118
119
103.187
458.777
.225 .636
DDIFF    Between Groups 
               Within Groups 
62.430
17693.27
1
118
62.430
149.943
.416 .520
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               Total    0
17755.70
0
119
Comments: The difference between the group with respect to sex is not 
significant. Hence the groups are comparable with respect to sex 
2. Comparison between groups with respect to Age
Sum of 
Squares 
df Mean 
Square
F Sig.
PRDIFF  Between Groups 
                Within Groups 
                Total 
659.994
48730.00
6
49390.00
0
2
117
119
329.997
416.496
.792 .455
SDIFF     Between Groups 
                Within Groups 
                Total   
1153.184
53085.74
1
54238.92
5
2
117
119
576.592
453.724
1.27
1
.284
DDIFF    Between Groups 
               Within Groups 
               Total    
395.440
17360.26
0
17755.70
0
2
117
119
197.720
148.378
1.33
3
.268
Comments: The difference between the group with respect to age is 
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not significant.
Hence the groups are comparable with respect to age.
3. Comparison between groups with respect to Weight 
Sum of 
Squares 
Df Mean 
Square
F Sig.
PRDIFF  Between Groups 
                Within Groups 
                Total 
1163.778
48226.22
5
49390.00
0
2
117
119
581.888
412.190
1.41
2
.248
SDIFF     Between Groups 
                Within Groups 
                Total   
1351.657
52887.26
8
54238.92
5
2
117
119
675.828
452.028
1.49
5
.228
DDIFF    Between Groups 
               Within Groups 
               Total    
215.859
17539.84
1
17755.70
0
2
117
119
107.929
149.913
.720 .489
Comments: The  difference  between  the  group  with  respect  to 
Weight is not significant.
Hence the groups are comparable with respect to Weight.
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1. Multiple comparison (pulse rate reduction) 
Dependent 
 Variable
(1) Group (J) group Mean 
Differenc
e (I-J)
Std.Erro
r
Sig 95% Confidence 
Interval
Lower 
Bound 
Upper 
Bound 
Pulse Rate 
Difference 
Control Verapamil 
Diltiazem 
Lidocaine 
44,0000*
35,3000*
39.5000*
2.7303
2.7303
2.7303
.000
.000
.000
36.6713
27.9713
32.1713
51.3287
42.6287
46.8287
Verapami
l  
Control
Diltiazem
Lidocaine 
-44.0000*
-8.7000*
-4.5000
2.7303
2.7303
2.7303
.000
.011
.612
-51.3287
-16.0287
-11.8287
-36.6713
-1.3713
2.8287
Diltiazem Control
Verapamil 
Lidocaine
-35.3000*
8.7000*
4.2000
2.7303
2.7303
2.7303
.000
.011
.760
-42.6287
1.3713
-3.1287
-27.9713
16.0287
11.5287
Lidocaine Control
Verapamil 
Lidocaine
-39.5000*
4.5000
-4.2000
2.7303
2.7303
2.7303
.000
.612
.760
-46.8287
-2.8287
-11.5287
-32.1713
11.8287
3.1287
*. The Mean difference is significant at the .05 level 
MULTIPLE COMPARISION(PULSE RATE REDUCTION)
The differences in  Pulse-rate reductions of verapamil , lidocaine 
and diltiazem were –44, –39.5  and -35.3 respectively. All the differences 
against  control  were  statistically  significant.   The  effects  of  verapamil 
found to be superior, followed by lidocaine. However, the difference in 
the effects between them was not  statistically  significant.  Their  effects 
were  almost  the  same.   Comparing  verapamil   against  diltiazem (-44-
(-35.3) = -8.7), the difference is statistically significant. That is, verapamil 
was superior to diltiazem. But, lidocaine was not statistically superior to 
64
the effects of diltiazem. 
1. All the treatments had better effect than the control
2. The leading drug is verapamil  having the difference of (-44) with 
control
3. Lidocaine is the next leading drug making the difference of 
   (-39.5) with control.  But, the difference found between verapamil 
and lidocaine is not  statistically significant.
4. Diltiazem was the least among the three. The effect of verapamil 
was found to be superior to diltiazem. But, lidocaine did not differ 
significantly from diltiazem.
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2. Multiple comparison (systolic blood pressure reduction) 
Dependent 
 Variable 
(1) Group (J) group Mean 
Difference 
(I-J)
Std.Error Sig 95% Confidence 
Interval
Lower 
Bound 
Upper 
Bound 
Systolic 
Blood 
Pressure 
difference 
Control Verapamil 
Diltiazem 
Lidocaine  
47.3000*
33.0667*
39.5333*
2.9606
2.9606
2.9606
.000
.000
.000
39.3529
25.1196
31.5863
55.2471
41.0137
47.4804
Verapamil Control
Diltiazem
Lidocaine 
-47.3000*
-14.2333*
-7.7667
2.9606
2.9606
2.9606
.000
.000
.059
-55.2471
-22.1804
-15.7137
-39.3529
-6.2863
.1804
Diltiazem Control
Verapamil 
Lidocaine
-33.0667*
14.2333*
6.4667
2.9606
2.9606
2.9606
.000
.000
.186
-41.0137
6.2863
-1.4804
-25.1196
22.1804
14.4137
Lidocaine Control
Verapamil 
Lidocaine
-39.5333*
7.7667
-6.4667
2.9606
2.9606
2.9606
.000
.000
.000
19.8440
11.3773
15.5440
30.4893
22.0227
26.1893
*. The Mean difference is significant at the .05 level 
Multiple comparison (Systolic blood pressure reduction) 
Comments: The differences in Systolic BP of verapamil , lidocaine and 
diltiazem were –47.3, –39.5 and –33.07 respectively. All the differences 
against  control  were  statistically  significant.   The  effects  of  verapamil 
found to be superior, followed by lidocaine. However, the difference in 
the effects between them was not  statistically  significant.  Their  effects 
were almost  the same.  Comparing verapamil  against  diltiazem (-47.3-
(-33.07)  =  -14.23),  the  difference  is  statistically  significant.  That  is, 
verapamil was superior to diltiazem. But, lidocaine was not statistically 
superior to the effects of diltiazem. 
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1. All the treatments had better effect than the control
2. The leading drug is verapamil  having the difference of (-47.3) with 
control
3. Lidocaine is the next leading drug making the difference of (-39.5) 
with  control.   But,  the  difference  found  between  verapamil  and 
lidocaine is not statistically significant.
4. Diltiazem was the least among the three. The effect of verapamil 
was found to be superior to diltiazem. But lidocaine did not differ 
significantly from diltiazem.
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3. Multiple comparison (diastolic blood pressure reduction) 
Dependent 
Variable 
(1) Group (J) group Mean 
Difference 
(I-J)
Std.Error Sig 95% Confidence 
Interval
Lower 
Bound 
Upper 
Bound 
Diastolic 
Blood 
Pressure 
Difference 
Control Verapamil 
Diltiazem 
Lidocaine  
25.1667*
16.7000*
20.8667*
1.9829
1.9829
1.9829
.000
.000
.000
19.8440
11.3773
15.5440
30.4893
22.0227
26.1893
Verapamil Control
Diltiazem
Lidocaine 
-25.1667*
-8.4667*
-4.3000
1.9829
1.9829
1.9829
.000
.000
.193
-30.4893
-13.7893
-9.6227
-19.8440
-3.1440
1.0227
Diltiazem Control
Verapamil  
Lidocaine
-16.7000*
8.4667*
4.1667
1.9829
1.9829
1.9829
.000
.000
.227
-22.0227
3.1440
-1.1560
-11.3773
13.7893
9.4893
Lidocaine Control
Verapamil  
Lidocaine
-20.8667*
4.3000
-4.1667
1.9829
1.9829
1.9829
.000
.193
.227
-26.1893
-1.0227
-9.4893
-15.5440
9.6227
1.1560
*. The Mean difference is significant at the .05 level 
Multiple comparison (diastolic blood pressure reduction) 
Comments: 
The differences in Diastolic BP of verapamil , lidocaine and diltiazem 
were -25.17,-20.87,-16.7 respectively. All the differences against control 
were  statistically  significant.   The  effects  of  verapamil  found  to  be 
superior,  followed by lidocaine.  However,  the difference in the effects 
between them was not statistically significant. Their effects were almost 
the  same.   Comparing  verapamil  against  diltiazem  (-25.17-(-16.7)  = 
-14.23), the difference is statistically significant. That is, verapamil  was 
superior to diltiazem. But, lidocaine was not statistically superior to the 
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effects of diltiazem. 
1. All the treatments had better effect than the control
2. The leading drug is verapamil  having the difference of (-25.17) 
with control
3. Lidocaine is the next leading drug making the difference of 
(-20.87) with control.  But, the difference found between verapamil and 
lidocaine is not  statistically significant.
4.Diltiazem was the least among the three. The effect of verapamil was 
found to be superior to diltiazem. But lidocaine did not differ 
significantly from diltiazem.
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COMPARISION WITH RESPECT TO QUALITY OF EXTUBATION
QUALITY
DRUG 1 2 3 4 5
CONTROL 5(16.6%) 16(53.3%) 5(6.6%) 4(13.3%) 0
VERAPAMIL 26(86.6%) 4(13.3%) 0 0 0
DILTIAZEM 17(56.6%) 11(36.6%) 2(6.6%) 0 0
LIDOCAINE 21(70%) 9(30%) 0 0 0
86.6% of patients given Verapamil during extubation had no cough 
or strain.56.6% &70% of patients in diltiazem &lidocaine group had no 
cough or strain during extubation respectively.But only 16.6% of patients 
in the control group had the best quality of extubation. Thus  Verapamil , 
lidocaine  & diltiazem  improved the quality of extubation.Verapamil is 
superior  to  lidocaine  &diltiazem  in  this  respect.  Futher  lidocaine  is 
associated with better quality of extubation than diltiazem.
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DISCUSSION
Anaesthesia is the process by which a patient is rendered, able to 
undergo  Surgery.  General  anaesthesia  uses  drugs  administered 
systemically to render the patient unaware of anything that is being done 
to or around him or her. It must be safe, not threating or unpleasant to the 
patient ,allow adequate surgical access to the operative site, and cause as 
little disturbance as possible to the internal homeostatic mechanisms. 
General  anaesthesia  has  many  advantages  such  as  making  no 
psychological  demand  on  the  patient,  allowing  complete  stillness  for 
prolonged periods  of  time,  facilitating  complete  control  of  the airway, 
breathing  and  circulation,  permitting  surgery  to  take  place  in  widely 
separated  areas  of  the  body  at  the  same  time  and  adapting  easily  to 
procedures of unpredictable duration or extent. Despite these advantages 
administration  of  general  anaesthesia  has  certain  disadvantages.  Apart 
from the less serious complications such as nausea, vomiting, sore throat, 
headache, shivering and delayed return to normal mental functioning the 
most feared aspect of general anaesthesia is its association with certain 
degree of physiological trespass. This physiological trespass can lead to 
major morbidity or mortality in a patient. The most susceptible phases of 
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general  anaesthesia  for  this  complication  to  occur  are  the  phases  of 
intubation and extubation. Thus the safe conduct of anaesthesia requires a 
high degree of preparation, vigilance and attention to detail till the process 
of extubation. 
In  this  study  the  provocation  of  cardiovascular  changes  with 
marked increase in heart rate and arterial blood pressure by extubation is 
confirmed. The heart rate increase from the baseline value is 40.70±10.96 
beats per minute during extubation. The systolic blood pressure increase 
is 33.20±12.50 mmHg from the baseline and the diastolic blood pressure 
increase is 19.73±1.86 mmHg from the baseline. Thus stress attenuation 
during extubation may be of value in preventing morbidity and mortality 
in  specific  patient  groups  such as  hypertensives  and those  undergoing 
cardiovascular or neurosurgical procedures. 
Myocardial  ischemia  may  occur  during  tracheal  extubation  in 
patients  with  coronary  arterial  disease (19,20).  The  occurrence  of 
perioperative myocardial ischemia during anaesthesia is associated with 
postperative myocardial infarction. As heart rate is a major controllable 
determinant  of  myocardial  oxygen  balance,  satisfactory  suppression  of 
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the tachycardic response to tracheal extubation may be beneficial. 
Further  in  this  study,  it  is  confirmed that  the  stress  response  to 
tracheal extubation can be attenuated with 0.1mg/kg of verapamil or 0.2. 
mg/kg of diltiazem or 1.5mg/kg of lidocaine.    
But the attenuative effect was greatest with 0.1mg/kg of verapamil 
followed  by  1.5mg/kg  of  lidocaine  which  is  followed  by  0.2mg/kg  of 
dilitazem. 
Although the precise mechanism responsible for the cardiovascular 
changes  during  tracheal  extubation  remains  to  be  elucidated, 
multifactorial stimuli during tracheal extubation, including wound pain, 
emergence from anaesthesia, and tracheal irritation, are involved in the 
events. The calcium channel blockers verapamil and diltiazem control the 
hypertension  and tachycardia  by  their  direct  vasodilatory  and  negative 
chronotropic  and  dromotropic  properties.  In  addition  the  potent  local 
anaesthetic  property  of  verapamil  could  have  contributed  to  the 
attenuation of laryngeal irritation which may be the reason for the better 
quality  of  extubation.  The  beneficial  effect  of  lidocaine  on  the 
hemodynamic sequences may be due, in part, to direct cardiac depression 
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and peripheral  vasodilation.  Intravenous   lidocaine  also  suppresses  the 
cough reflex. 
In this study, none of the patients who received the drugs developed 
sustained bradycardia    (HR <50bpm )  or  profound hypotension (SAP 
<80mmHg)  or sinoatrial  or  atrioventricular  block sufficient  to  require 
pressor or sympathomimetic drugs after extubation. 
Further  the quality  of  extubation is also enhanced by the use of 
these drugs during extubation. The quality of extubation is found to be 
superior with that of verapamil than that of lidocaine or diltiazam. 
Verapamil  is  also  highly  cost  effective  than that  of  lidocaine  or 
diltliazem. Lidocane is superior to diltiazem in cost effectiveness.
Considering  all  the  above  said  factors  verapamil  in  the  dose  of 
0.1mg/kg is the drug of choice for tracheal extubation among the 3 drugs. 
Lidocaine  1.5mg/kg  is  the  not  drug  of  choice.  If  both  verapamil  and 
lidocaine are not available diltiazam in the dose of 0.2mg/kg may be used 
with substantial benefit.
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CONCLUSION
 
1. Tracheal extubation is associated with increase in pulse rate and blood 
pressure. 
PR increase – 40.70 beats per min 
SBP increase – 33.20 mmHg
DBP increase – 19.73 mmHg
2. Verapamil,  lidocane  and  diltiazem  all  improve  the  quality  of 
extubation. 
3. Verapamil  0.1mg/kg  is  superior  to  lidocaine  and  diltazem  in 
attenuating stress response during extubation.  lidocaine 1.5mg/kg is 
superior to diltiazem in attenuating the stress response to extubation. 
4. Verapamil, Lidocaine and Diltiazem all attenuate the stress response to 
extubation. 86.6% of patients given Verapamil had no cough or strain 
(quality1 extubation). 56.6% of patients in diltiazem group and 70% of 
patients in lidocaine group also had quality 1 extubation i.e., no cough 
or strain. But only 16.6% of patients in the control group had no cough 
or strain during extubation.        
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                                                     PROFORMA
NAME :
AGE :
SEX :
WEIGHT :
DIAGNOSIS :
SURGERY DONE :
ASA PHYSICAL STATUS :
GROUP: CONTROL    /VERAPAMIL   / DILTIAZEM  /  LIDOCAINE
   (TO BE TICKED OVER THE SPECIFIC GROUP)
QUALITY OF EXTUBATION:
1 NO COUGH OR STRAIN
2 VERY SMOOTH, MINIMAL COUGH
3 MODERATE COUGH
4 MARKED COUGH OR STRAIN
5 POOR EXTUBATION
   (TO BE TICKED OVER THE SPECIFIC QUALITY )
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MONITORED PARAMETERS :
TIME PULSE RATE 
(Per Minute)
SYSTOLIC 
BLOOD 
PRESSURE (mm 
of Hg) 
DIASTOLIC 
BLOOD 
PRESSURE (mm 
of Hg)
PRE OPERATIVE
0 MIN (end of 
surgery)
1 MIN
2 MIN
3 MIN
4 MIN
5 MIN
6 MIN
7 MIN
8 MIN
9 MIN
10 MIN
SIDE EFFECTS:
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